Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | FABP3 | P05413 | 3/20 | 0.39 |
| ▸ | FABP4 | P15090 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132021 | 1.00 | PTGS2 (0.40) | PTGS2FABP3FABP4ESR1KCNJ6 | |
| SCHEMBL1131833 | 0.86 | MDM2 (0.47) | FABP3FABP4CMKLR1 | |
| SCHEMBL1131835 | 0.86 | MDM2 (0.47) | FABP3FABP4CMKLR1 | |
| SCHEMBL1131608 | 0.79 | ESR1 (0.40) | PTGS2FABP3FABP4ESR1KCNJ6 | |
| SCHEMBL1131567 | 0.78 | CMKLR1 (0.39) | FABP3FABP4CMKLR1FAAH | |
| SCHEMBL1131977 | 0.77 | FABP3 (0.34) | PTGS2FABP3FABP4CMKLR1APLNR | |
| SCHEMBL1131611 | 0.75 | PTGS2 (0.43) | PTGS2FABP3FABP4ESR1KCNJ6 | |
| SCHEMBL5861842 | 0.75 | PTGS2 (0.43) | PTGS2FABP3FABP4ESR1KCNJ6 | |
| SCHEMBL1131986 | 0.75 | CMKLR1 (0.36) | FABP3FABP4CMKLR1FAAH | |
| SCHEMBL1132014 | 0.74 | SLC5A1 (0.37) | MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |